Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On May 7, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the first quarter of 2024.</li><li> The company will be hosting an investor event in June 2024 to present interim results from the ongoing Phase 2 trial of mavorixafor in chronic neutropenia (CN).</li><li>The company has initiated the launch of XOLREMDI (mavorixafor) for use in patients 12 years of age and older with WHIM syndrome.</li></ul>

On May 7, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the first quarter of 2024. The company will be hosting an investor event in June 2024 to present interim results from the ongoing Phase 2 trial of mavorixafor in chronic neutropenia (CN).The company has initiated the launch of XOLREMDI (mavorixafor) for use in patients 12 years of age and older with WHIM syndrome.

XFOR: Data from Phase 2 CN Trial Expected in June 2024 